Edwards Lifesciences Corp

EW

New York Stock Exchange. Currency in USD

73.43 +0.42 ( +0.58% )

Real time prices: December 19

Market Cap.
45.40B
Beta (5Y monthly)
1.03
Price/Earnings
30.84
EPS (TTM)
2.35
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
3.55M
1y Target Est.
92.43
Day's Range
72.25
-
74.12
52 Week's Range
67.13
-
131.10

Historical Summary

Performance
EPS growth
Share Buybacks

About Edwards Lifesciences Corp

Sector
Healthcare
Industry
Medical Devices
Website
https://www.edwards.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
621.64M
Employees
15700
Address
One Edwards Way, Irvine, CA, United States, 92614
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Latest news

Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options
Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements...
By Zacks Investment Research - 6 weeks ago

Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'

Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be...
By Benzinga - 6 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022

Upgrades According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was...
By Benzinga - 7 weeks ago

JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday

Morgan Stanley raised JPMorgan Chase & Co. (NYSE: JPM) price target from $126 to $153....
By Benzinga - 7 weeks ago

Stocks To Watch: Oil Plays, Lowe's, Southwest Airlines And Lululemon In Focus
Stocks To Watch: Oil Plays, Lowe's, Southwest Airlines And Lululemon In Focus

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview...
By Seeking Alpha - 8 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022

Upgrades For UDR Inc (NYSE:UDR), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight....
By Benzinga - 8 weeks ago

Expert Ratings for Edwards Lifesciences
Expert Ratings for Edwards Lifesciences

Over the past 3 months, 15 analysts have published their opinion on Edwards Lifesciences (NYSE:EW)...
By Benzinga - 9 weeks ago

Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands

Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to...
By Benzinga - 9 weeks ago